A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
← catalyst calendarSponsored by Recursion Pharmaceuticals Inc. (industry) · RXRX — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
18actual
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study was terminated due to sponsor decision. This decision was not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-15 | actual | When the study began enrolling |
| Primary completion | 2025-02-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- AXIN1 Gene Mutation
- APC Gene Mutation
- Solid Tumor
Intervention
- Drug: REC-4881
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose Limiting Toxicities
measured Up to 24 months
Objective Response Rate
measured Up to 24 months
Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed